Phase 1 Study of R-CVP or R-GDP in Combination With CMC-544 in NHL

• Research type

  Research Study

• Full title

  An Open-label, Phase 1 Study of R-CVP or R-GDP in Combination With Inotuzumab Ozogamicin in Subjects With CD22-Positive Non-Hodgkin’s Lymphoma

• IRAS ID

  37151

• Contact name

  Andrew Davies

• Contact email

  a.davies@southampton.ac.uk

• Sponsor organisation

  Worldwide Biophmarmaceutical Business clinical Operations Grouop, IPC 4G

• Eudract number

  2009-015497-35

• Clinicaltrials.gov Identifier

  NCT01055496

• Research summary

  Esceeds word count do not publish

• REC name

  South Central - Berkshire Research Ethics Committee

• REC reference

  10/H0505/28

• Date of REC Opinion

  15 Apr 2010

• REC opinion

  Further Information Favourable Opinion